Stevens-Johnson Syndrome after Sertraline

Sir,
Sertraline (Zoloft®) is a new selective inhibitor of serotonin re-uptake. This family of antidepressant drugs is considered to be safe, and cutaneous adverse reactions have rarely been reported (1). We report here a patient who developed Stevens-Johnson syndrome (SJS) after starting treatment with sertraline (Zoloft®).

A 96-year-old woman was admitted with a cutaneous and mucosal eruption. Sertraline and arginine chlorhydrate (Arginine Veyron®) treatment had been initiated 3 weeks before the eruption. Sertraline had replaced paroxetine (Deroxat®), initiated 7 weeks before the eruption for depression. Her general condition was good, and her temperature was 37°C. The cutaneous lesions were found on the face, trunk and proximal parts of the limbs, and were erythematous or purpuric, with an atypical flat target appearance, without significant epidermal detachment. Nikolsky’s sign was negative. She had painful oral erosions and conjunctivitis. Histological examination of a skin biopsy showed total necrosis of the epidermis, direct immunofluorescence was negative, and the blood cell count was normal.

Serology for herpes virus I and II showed previous exposure was negative, and the blood cell count was normal.

The diagnosis of SJS was retained because of the association of macular and purpuric lesions with an atypical flat target appearance involving the trunk and face has been observed in 2 cases (8).

Control of serology for Mycoplasma pneumoniae was negative. Sertraline and arginine chlorhydrate treatment were withdrawn and the cutaneous eruption disappeared in 7 days. Control of serology for Mycoplasma pneumoniae was negative.

The cutaneous lesions were found on the face, trunk and proximal parts of the limbs, and were erythematous or purpuric, with an atypical flat target appearance, without significant epidermal detachment. Nikolsky’s sign was negative. She had painful oral erosions and conjunctivitis. Histological examination of a skin biopsy showed total necrosis of the epidermis, direct immunofluorescence was negative, and the blood cell count was normal. Serology for herpes virus I and II showed previous exposure was negative. Sertraline and arginine chlorhydrate treatment were withdrawn and the cutaneous eruption disappeared in 7 days. Control of serology for Mycoplasma pneumoniae was negative.

The diagnosis of SJS was retained because of the association of macular and purpuric lesions with an atypical flat target appearance involving the trunk and proximal limbs, 2 different mucosal sites and total necrolysis of the epidermis (2). This syndrome is usually related to drug intake (3), and serology for herpes and Mycoplasma pneumoniae were negative. According to the standards of the French drug surveillance system, sertraline and arginine chlorhydrate were the only culprit drugs (4). Imputability of arginine chlorhydrate is nil, because it is an amino acid, and no side effect has been reported with this drug. One case of erythema multiforme with involvement of the trunk and face has been reported with sertraline (5) but, to our knowledge, this is the first case of SJS observed with sertraline treatment. Nevertheless, SJS and toxic epidermal necrolysis (TEN) have been reported with 2 other members of the family of selective inhibitors of serotonin re-uptake (fluvoxamine and fluoxetine) (6, 7). Cross-reactivity between several members of this family has been observed in 2 cases (8). In the case reported here, paroxetine was not imputable because it had been initiated 7 weeks before the eruption. If a severe cutaneous side effect (SJS or TEN) occurs, it would be better to change the drug family (8).

REFERENCES


Accepted January 21, 1999

V. Jan1, C. Toledano1, L. Machet1, M.C. Machet2, L. Vaillant1 and G. Lorette1
Departments of 1Dermatology and 2Pathology, CHU Troussseau, F-37044 Tours Cedex, France.

Accepted March 10, 1999.

Ida-Marie Stender and Hans Christian Wulf
Department of Dermatology, Bispebjerg Hospital D92, University of Copenhagen, Bispebjerg Bakke, DK-2400 Copenhagen, Denmark. E-mail: ims01@bbh.hosp.dk.